vasopharm GmbH is a Wurzburg, Germany–based drug development company focused on small molecule therapeutics for treatment of traumatic brain injury (TBI). Its lead candidate, VAS203 (Ronopterin), is in the Phase III NOSTRA trial assessing efficacy and safety in moderately to severely injured closed-head TBI patients. The EMA has granted VAS203 orphan drug designation for moderate to severe brain injury. The company positions VAS203 as avoiding unwanted side effects while delivering strong clinical efficacy versus current acute TBI approaches. vasopharm plans to use the new financing to complete CMC scale-up and stability testing in preparation for commercial-scale production and to support a potential Marketing Authorization Application (MAA) to the EMA, as well as to explore additional indications. Founded in July 1998 as a spin-off from the University of Würzburg Medical School and led by CEO Christian Wandersee, vasopharm has raised about €50m to date through several financing rounds. vasopharm develops small-molecule therapeutics that modulate the NO/cGMP signaling cascade and its functional counterpart NOX. Its lead candidate, VAS203, is an analogue of the natural co-factor biopterin and is believed to selectively downregulate inducible NOS (iNOS) without significantly inhibiting other NOS enzymes. The company is led by CEO Christian Wandersee and is based in Wuerzburg, Germany. vasopharm raised €20m in funding to support a pivotal European Phase III study of VAS203 in moderate to severe traumatic brain injury (TBI). All preparatory groundwork for the clinical trial was completed over the prior 12 months and a "first patient in" was expected in H1 2016. The financing and upcoming Phase III represent the company’s immediate clinical and operational priorities.

Total raised

$32M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2019